ITRM (iterumtx.com) רווח נקי למניה (EPS TTM)

Despite high launch costs for new products, Iterum Therapeutics plc (ITRM) is protected by antibiotic formula patents and stringent FDA controls. The current rolling annual EPS visualizes financial stability, where -0.72 determines the latest valuation metric. The risks for Iterum Therapeutics plc (ITRM) are mitigated by the development of modern drugs for the home treatment of severe urinary tract infections, which guarantees stable demand.

The metric is calculated as the ratio of total net income over the last four quarters to the total number of shares. This metric determines the real return on each ownership stake, capturing business consolidation phases. For Iterum Therapeutics plc (ITRM), regulatory procedure expenses are covered by reserves, which directly impacts the bottom line. By analyzing the TTM earnings per share trend, an investor assesses the balance between the market price and asset value. A local breakout of this line may be a deceptive signal.